Norbert Ndjeka

4 ta ish

National Health Laboratory Service

1. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

   Nafees Ahmad, Shama D. Ahuja, Onno W. Akkerman +97

   Sharh maqolaOAOchiq kirish20184 iqtibos

   ABIABI:AkademIndex/2026.other.034216

2. Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosis

   S.K. Abidi, Jay Achar, M.M. Assao Neino +34

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyEuropean Respiratory Journal20191 iqtibos

   ABIABI:AkademIndex/2019.article.000020

3. Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026

   Aastha Gupta, Sandeep Juneja, Victor Babawale +12

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyPLoS ONE20240 iqtibos

   ABIABI:AkademIndex/2024.article.000247

4. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

   Anthony J. Garcia‐Prats, Maria Garcia‐Cremades, Vivian Cox +97

   Sharh maqolaOAOchiq kirishTuberculosis Research and EpidemiologyThe Lancet Child & Adolescent Health20250 iqtibos

   ABIABI:AkademIndex/2025.review-article.000036